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BACKGROUND: UK residents’ healthcare is free of charge but uptake varies. Cancer survival is inferior to that of other Western
European countries. We have used cancer registry data to assess factors associated with access to diagnosis and treatment of lung
cancer in northern England.
METHOD: We assigned 34923 lung cancer patients diagnosed between 1994 and 2002 to quartiles for the deprivation score
associated with their postcode and for the travel time to the relevant healthcare facility. Odds ratios, adjusted for age and sex, for
undergoing interventions were calculated relative to the least deprived quartile living closest to the facility. The odds ratio for
receiving chemotherapy for small-cell lung cancer (SCLC) was calculated according to the type of hospital where it was diagnosed.
RESULTS: The odds ratio for attainment of a histological diagnosis for the least deprived/furthest residence group was 0.83 (95%
confidence 0.70–0.97) for the most deprived/nearest residence group was 0.74(0.62–0.87) and for the most deprived/furthest
residence group it was 0.61 (0.49–0.75). The corresponding odds ratios for receipt of any active treatment were 0.93 (0.80–1.07),
0.74 (0.64–0.86), and 0.55 (0.46–0.67). The odds ratios for receipt of chemotherapy for SCLC were 1.27 (0.89–1.82), 1.21
(0.85–1.74) and 0.81 (0.52–1.28). Odds ratios for undergoing surgery for non-small cell lung cancer using (1) travel time to
diagnosing hospital were 0.88 (0.70–1.11), 0.74 (0.59–0.94) and 0.60 (0.44–0.84). Using (2) travel time to a thoracic surgery facility
they were 0.83 (0.65–1.06), 0.70 (0.55–0.89) and 0.55 (0.49–0.76).
CONCLUSION: Living in a deprived locality reduces the likelihood of undergoing definitive management for lung cancer with the
exception of chemotherapy for SCLC. This is amplified by travel time to services.
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The Eurocare comparisons of cancer survival among European
populations have consistently shown that the constituent countries
of the United Kingdom have inferior survival compared with peer
group countries for many sites of cancer even though the National
Health Service (NHS) provides diagnostic and treatment services
free of charge. This is notably true for lung cancer as is confirmed
by the most recent data (Berrino et al, 2007). Detailed studies of
the UK service are required to determine how this may arise.
Moreover, within the United Kingdom survival has been shown
to be generally poorer for those from more deprived areas. For the
majority of adult tumours a significantly greater proportion of
patients from the most affluent areas survive to 5 years after
diagnosis than those from disadvantaged neighbourhoods. It has
been suggested that this is associated with a combination of factors
acting to the disadvantage of those from less affluent areas. These
include presence of comorbidities precluding aggressive treat-
ments, patient delay in seeking medical advice and delay in referral
acting through later stage of disease at diagnosis, and differential
access to specialist treatment. However, the strength of association
between these factors and survival varies between studies and
tumour site (Woods et al, 2006). In the case of lung cancer there is
evidence that patients from more deprived areas of the United
Kingdom are significantly less likely to receive active treatment in
general (Jack et al, 2006) and chemotherapy in particular
(Campbell et al, 2002; Patel et al, 2007). Similarly Earle et al
(2000) writing at a time when chemotherapy for non-small cell
lung cancer was not standard management in the United Kingdom,
found that higher socioeconomic status patients in the USA were
more likely to receive this treatment. Previous workers have also
shown that receipt of treatment can be associated with the
specialism of the doctor first seen at hospital (Jack et al, 2006).
The work reported here was undertaken as part of a larger study
examining the effect of travel time to health services on survival
and treatment for five common cancers using data supplied by the
Northern and Yorkshire Cancer Registry and Information Service
(NYCRIS). It gave the opportunity to study the separate influence
of deprivation and geographic access to specialist services and
their influence on treatment received for lung cancer in an area of
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sEngland showing a wide range of both deprivation and geographic
access to health services.
In the United Kingdom, NHS outpatients’ access to all services
is through their general practitioner (GP) with whom they will
normally have initial contact except when emergency services
are required. Direct access to hospital-based specialists is not
available. General hospitals provide a wide variety of services but
certain disciplines have been concentrated in specialist centres.
In the context of lung cancer, thoracic surgery and radiotherapy
were centralised more than 45 years ago; this policy was endorsed
in England, within the national Cancer Plan (The NHS Cancer
Plan, 2000).
Histological confirmation of lung cancer diagnosis is the
baseline point in management and the extent of this previously
showed differences between the UK and The Netherlands
(Crawford and Atherton, 1994). In this analysis, we investigate
the influence of social and geographical factors on the attainment
of histological diagnosis and on receipt of any form of active
treatment (surgery, chemotherapy or radiotherapy). We further
investigate their influence on receipt of the definitive optimal
treatment, surgery in the case of non-small cell lung tumours and
chemotherapy in the case of small-cell cancer. The indicators we
have independently chosen are also those used in the National
Lung Cancer Audit (2007).
PATIENTS AND METHODS
Records of lung cancer registrations held by the NYCRIS during
the period 1994–2002 were used. After excluding mesothelioma,
atypical pathology types and cases only diagnosed postmortem a
total of 34923 patient records were available for analysis.
The process of developing a database appropriate for geo-
graphical analyses from the Registry records has been described
elsewhere (Jones et al, 2008a). This database included the
histological diagnosis obtained and the treatment or treatments
delivered in the period up to 6 months, but usually shorter,
following diagnosis. Car travel times from the patient’s residence
to healthcare providers were estimated in a geographical informa-
tion system (ArcGIS 9.2) using the shortest road route and average
driving speeds along specific classes of roads. An independent
survey of 475 patients attending cancer clinics in the same study
area had already established that 87% of patients made the journey
by car and that travel estimates based on the road network and
average speeds were closely related to actual car journey times
reported by patients (Haynes et al, 2006).
With the exception of the thoracic surgery analysis, the
institution chosen for analysis of access was the closest NHS
facility that provided services for diagnosis of lung cancer, that is,
the closest facility to which the GP might refer a patient for this
purpose. A specialist hospital that provided non-surgical treatment
but not diagnosis for cancer was excluded from this and some very
small hospitals, attended by fewer than 1% of the patients, and
private healthcare providers, which were attended by fewer than
400 patients in the database, were also excluded.
We explored the characteristics of the closest hospital as
determinants for receipt of chemotherapy, comparing designated
cancer centres with district general hospitals that hosted a non-
surgical oncology service and those that did not.
Deprivation was determined from the Index of Multiple
Deprivation (IMD), an area-level measure associated with the
postcode (Office of the Deputy Prime Minister, 2004). We removed
the access to services domain from the IMD scores so as to
eliminate the potential of double counting.
Patients were divided into equal quartiles for deprivation and
for travel time to the closest hospital providing diagnostic access.
All statistical analyses were undertaken using the SPSS for
Windows 14 package (2005, SPSS Inc., Chicago, IL, USA). Binary
logistic regression was used to examine the relationship between
the odds of undergoing an intervention and deprivation and travel
time. Models were adjusted for the effects of patient age and sex
(Patel et al, 2007, Jones et al, 2008a,b). The stage of the disease was
not recorded in the NYCRIS data set. It is likely that this patient
feature has a causal effect in patients being denied thoracic surgical
treatment. The likelihood of undergoing this was determined for
18324 non-small cell patients. For small-cell lung cancer patients
(n¼5510) likelihood of receiving chemotherapy was determined.
The intent, curative or palliative could not be determined from this
database.
RESULTS
Of the 34923 patients, 26069 (74.6%) had the diagnosis of
lung cancer confirmed histologically. 8816 (25.2%) did not have
a histological diagnosis and for 38 (0.1%) no information
regarding histological diagnosis was available. Just 1.1% of
the sample attended a private healthcare provider for initial
hospital treatment. Some 5783 (16.6%) received chemotherapy;
13857 (39.7%) received radiotherapy and 3552 (10.2%) underwent
surgery to the thorax. In total, 19667 (56.3%) received at least one
of these treatments. In this study, 3335 (18.2%) of the 18324 non-
small cell lung cancer patients underwent thoracic surgery. Then,
3619 (65.7%) of the 5510 small-cell lung cancer patients received
chemotherapy.
Table 1 shows the distribution of the 34923 patients according
to deprivation and travel quartiles. Baseline categories were travel
quartile 1, which represents the shortest travel time to hospital,
and deprivation quartile 1, which represents the least deprived.
The 25th percentile travel time was 7.00min, the median 10.91min
and the 75th percentile 15.49min. In the study area the majority of
hospitals are located in urban centres and the proportion of the
most deprived patients was greatest in the closest travel quartile
and least in the furthest.
For histological confirmation of diagnosis (Table 2), there was
a strong trend for patients living in more deprived areas to be
less likely to be confirmed. Although there was no effect of travel
time overall, the magnitude of the trend with deprivation tended
to increase with increasing travel time so the lowest odds of
confirmation was observed among those residing in the most
deprived and furthest travel time quartile. Patients in the
intermediate groups for deprivation and travel time did not differ
greatly in the rate of histological confirmation from the reference
group, and the odds ratios did not reach statistical significance.
For receipt of any active treatment, that is surgery, radiotherapy
or chemotherapy, the decrease in receipt of treatment with
increasing deprivation was once more apparent with the strongest
evidence of distance decay, that is the tendency for utilisation of a
service to decline with increasing distance between the patient’s
residence and its location, again being evident for the most
deprived group living at the longest travel times (Table 3).
Table 1 Number of patients (%) by quartiles of deprivation and travel
time to the closest hospital providing diagnostic services
Deprivation
Travel time 1 Least 2 3 4 Most All quartiles
1. Closest 1134 (3.2) 1976 (5.7) 2181 (6.2) 3465 (9.9) 8756
2. 1579 (4.5) 2186 (6.3) 2365 (6.8) 2587 (7.4) 8717
3. 2104 (6.0) 2379 (6.8) 2502 (7.2) 1737 (5.0) 8722
4. Furthest 3915 (11.2) 2193 (6.3) 1683 (4.8) 937 (2.7) 8728
All quartiles 8732 8734 8731 8726 Total
34923
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definitive optimal treatment for non-small cell lung cancer, in
relation to deprivation and travel time firstly to the nearest
hospital providing diagnostic services (Table 4a) and also offering
this treatment (Table 4b). There was again a tendency for the more
deprived patients, and again the effect was greatest for those in the
most deprived quartile and furthest from hospital, irrespective of
whether this was the closest diagnosing hospital or the closest
thoracic surgery unit. Patients whose closest NHS diagnostic
unit was a District General Hospital (DGH), regardless of whether
there was a medical oncology service present, were significantly
less likely to undergo thoracic surgery compared with those
whose closest hospital was a cancer centre. (DGH with oncology,
OR¼0.87, 95% CI¼0.76–0.99, P¼0.036; DGH without oncology,
OR¼0.88, 95% CI¼0.80–0.96, P¼0.005, all adjusted for age
and sex)
For administration of chemotherapy to patients with small-cell
lung cancer (the optimal treatment in such patients), there was no
consistent variation with social deprivation or with distance
(Table 5) and, while the lowest odds of receiving the treatment was
again among those in the most deprived and furthest quartile, this
did not reach statistical significance. When such patients attended
a DGH which included oncology services, usually medical
oncology, the odds ratio for receiving chemotherapy compared
with patients attending a designated cancer centre was 0.94 (95%
CI 0.77–1.16); those attending a District General Hospital without
oncology were less likely to receive this treatment (OR 0.78, 95% CI
0.68–0.90).
DISCUSSION
In this study, we found that lung cancer patients living in the most
deprived areas were the least likely to receive histological
diagnosis, active treatment and thoracic surgery for non-small
cell cancer. Although there was no overall effect of travel time to
Table 2 Odds ratios (95% CI) for attaining histological diagnosis by quartiles of deprivation and travel time. All values adjusted for age and sex
Deprivation
Travel time 1 Least 2 3 4 Most All quartiles
1. Closest 1 0.79* (0.66–0.94) 0.69** (0.58–0.82) 0.74** (0.62–0.87) 1
2. 0.88 (0.73–1.07) 0.81* (0.67–0.96) 0.80* (0.67–0.95) 0.75** (0.63–0.89) 1.05 (0.97–1.13)
3. 0.90 (0.76–1.08) 0.87 (0.73–1.04) 0.87 (0.73–1.04) 0.78** (0.65–0.94) 1.13** (1.05–1.21)
4. Furthest 0.83* (0.70–0.97) 0.78** (0.65–0.93) 0.78** (0.65–0.94) 0.61** (0.49–0.75) 1.02 (0.95–1.09)
All quartiles 1 0.93* (0.86–1.00) 0.90** (0.83–0.96) 0.84** (0.78–0.90)
* Po0.05, ** Po0.01.
Table 3 Odds ratios (95% CI) for receipt of any active treatment by quartiles of deprivation and travel time. All values adjusted for age and sex
Deprivation
Travel time 1 Least 2 3 4 Most All quartiles
1. Closest 1 0.85* (0.73–1.00) 0.76** (0.65–0.89) 0.74** (0.64–0.86) 1
2. 0.91 (0.77–1.07) 0.85* (0.72–0.99) 0.76** (0.65–0.88) 0.74** (0.64–0.86) 1.00 (0.93–1.06)
3. 0.89 (0.76–1.04) 0.84* (0.72– 0.98) 0.80** (0.69–0.93) 0.78** (0.66–0.92) 1.03 (0.97–1.10)
4. Furthest 0.93 (0.80–1.07) 0.83* (0.71–0.97) 0.71** (0.60–0.83) 0.55** (0.46–0.67) 1.01 (0.95–1.08)
All quartiles 1 0.91** (0.86–0.97) 0.82** (0.77–0.88) 0.79** (0.74–0.84)
* Po0.05, ** Po0.01.
Table 4 Odds ratios (95% CI) of undergoing thoracic surgery for non-small cell lung cancer (n¼18324 patients) by quartiles of deprivation and travel
time to (a) the closest diagnosing hospital and (b) the closest thoracic surgery unit. All values adjusted for age and sex
Deprivation
Travel time 1 Least 2 3 4 Most All quartiles
(a)
1. Closest 1 0.87 (0.67–1.12) 0.72* (0.56–0.93) 0.75* (0.59–0.94) 1
2. 0.99 (0.76–1.29) 0.78 (0.60–1.00) 0.85 (0.67–1.09) 0. 69** (0.54–0.88) 1.01 (0.91–1.12)
3. 0.87 (0.68–1.12) 0.84 (0.65–1.07) 0.75* (0.58–0.96) 0.86 (0.66–1.11) 1.03 (0.93–1.15)
4. Furthest 0.88 (0.70–1.11) 0.81 (0.63–1.04) 0.65** (0.49–0.85) 0.60** (0.44–0.84) 0.99 (0.89–1.10)
All quartiles 1 0.90* (0.81–1.00) 0.82** (0.74–0.91) 0.80** (0.72–0.89)
(b)
1. Closest 1 0.91 (0.69–1.19) 0.80 (0.61–1.04) 0.70** (0.55–0.89) 1
2. 0.86 (0.65–1.13) 0.81 (0.62–1.05) 0.71** (0.54–0.92) 0. 75* (0.58–0.98) 0.98 (0.88–1.09)
3. 0.79 (0.61–1.02) 0.65** (0.50–0.85) 0.64** (0.49–0.83) 0.61** (0.46–0.81) 0.86** (0.77–0.95)
4. Furthest 0.83 (0.65–1.06) 0.71* (0.54–0.92) 0.62** (0.46–0.82) 0.55** (0.39–0.76) 0.91 (0.82–1.01)
All quartiles 1 0.90* (0.81–1.00) 0.82** (0.74–0.91) 0.80** (0.72–0.89)
All values adjusted for age and sex. * Po0.05, ** Po0.01.
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shospital across the sample of patients, travel time was found to
amplify the effects of deprivation, with the lowest likelihood of
receiving these treatments falling within the most distant and
deprived quartile.
The IMD 2004 score on which this is based is allocated to a
Lower Level Super Output Area (SOA) with a population of
approximately 1500 (Office of the Deputy Prime Minister, 2004).
The relevant SOA for an individual patient is identified from the
postcode. While there is inevitably variation in socioeconomic
circumstances between individuals in that population the effect of
this on the interpretation we have given to these data will be to
diminish the differences we have observed if favoured residents of
a deprived SOA increase the intervention rate and deprived
residents of an affluent SOA decrease it.
The consistent observation that patients with lung cancer
fare worse in the United Kingdom than they do in socioeconomic
peer group nations of Western Europe requires careful scrutiny.
The data collected by cancer registries enable this observation
to be made and in this analysis we use these data to explore
socioeconomic influences in relation to the geography of
healthcare provision. The developing process of detailed collection
of data about the management of individuals takes the study
further. The recently published National Lung Cancer Audit for
England and Wales has shown a similar pattern to previous
analyses in spite of the development and refinement of referral
guidelines for people with suspected cancer. Of patients accrued
into the 2006 audit, only 48% had been referred as requiring
investigations for lung cancer by their GP (National Lung Cancer
Audit, 2007). Before the guidance was published, the figure was
virtually the same (Melling et al, 2002). The proportion of patients
undergoing thoracic surgery and other specific treatments was low
compared with other West European countries.
Travel times were based on the nearest appropriate hospital,
which is not necessarily the same as the hospital to which each
patient was actually referred. Although 94% of patients who
received radiotherapy and 72% of patients who received thoracic
surgery in our sample were treated at their nearest facility, only
44% of patients received chemotherapy at their closest unit. We
assume that the patients who are willing to travel further to be
treated at a preferred hospital are generally not those with
transport difficulties. It was necessary to use the closest unit
for comparative purposes because there was no hospital of
actual referral for patients who were not treated. Furthermore,
this approach eliminates any bias caused by a GP referring
fitter patients to a specialist service while unfit individuals are
seen locally.
The indicators we chose are the same as those included in the
National Audit because they are those where there is variation. Our
work may be criticised because our patients were diagnosed before
the full implementation of the reforms of cancer services that have
taken place in the United Kingdom over the past 8 years. Our
response is that these changes concerned the organisation and
practice in secondary care facilities, principally hospitals and had
no influence on events before the involvement of the specialist
team. The differences in indicators associated with deprivation
associated with the immediate area of residence of the patient and
the travel time to the closest healthcare institution with the
facilities to make the diagnosis of lung cancer are more likely to
reflect factors affecting access to the hospital, not what happens
within it.
In investigating the effect of these we add detail to the smaller
studies conducted in Scotland which showed that patients with
lung cancer were diagnosed with more advanced disease with
increasing distance of a cancer centre from their residence and that
independently of age, stage and other factors deprived people were
less likely to receive chemotherapy (Campbell et al, 2001, 2002).
The NYCRIS data set contains virtually no information about
stage at presentation. It is very likely that the disadvantage
of socioeconomic deprivation and prolonged travel to services is
manifest in more advanced stage at presentation. This would
mainly affect the use of thoracic surgery, a treatment, which is
reserved for patients with disease confined to structures that
can be excised. However, histological diagnosis is an important
diagnostic step in all patients so the stage of disease is not
expected to influence its attainment. Where surgery is not possible,
radiotherapy or chemotherapy may be offered unless contra-
indicated by comorbidity or poor performance status so stage of
disease is not likely to influence the likelihood of being denied any
treatment as outlined in Table 3.
The general finding for active treatment is that deprivation is
strongly associated with reduced delivery and for the most
deprived this is exacerbated by distance between residence and
hospital. It is most likely that this relates to the events before
attendance at the hospital, especially the involvement of primary
care in attaining the diagnosis of a tumour. The confirmation of
the histological diagnosis is used as a marker of the starting point
for active management; this may not be attained if patients are felt
to be too unfit for investigative tests, which raises the question of
what opportunities were missed in primary care. The findings of
Hamilton et al (2005), derived from primary care studies in the
city of Exeter, have shown the tendency for patients ultimately
diagnosed with lung cancer to have a record of attendances with
relevant symptoms over several months preceding the diagnosis.
The fact that the effects were less for SCLC chemotherapy is
likely to reflect the fact that this type of the disease is rapidly
progressive so that a relatively high proportion of patients who in
fact had SCLC were considered too unwell for diagnostic
procedures and so are never identified.
The lack of distance decay in the histological confirmation rate
for patients of intermediate deprivation suggests that travel to
hospital was less of a barrier for people from average socio-
economic backgrounds than it was for the group from the most
deprived areas. An explanation of this might be that the closest
quartile is affected by the problems of delivery of primary care
services in an inner city area, most hospitals are located in urban
areas. This appears to be less important in suburban areas with
Table 5 Odds ratio (95% CI) of receiving chemotherapy for small cell lung cancer (n¼5510 patients) by quartiles of deprivation and travel time. All
values adjusted for age and sex
Deprivation
Travel time 1 Least 2 3 4 Most All quartiles
1. Shortest 1 1.24 (0.83–1.85) 0.92 (0.63–1.35) 1.21 (0.85–1.74) 1
2. 1.23 (0.81–1.87) 1.40 (0.95–2.06) 1.11 (0.76–1.62) 1.29 (0.88–1.89) 1.14 (0.96–1.34)
3. 1.49* (1.01–2.21) 1.50* (1.03–2.20) 1.45 (0.99–2.12) 1.31 (0.87–1.98) 1.31** (1.11–1.55)
4. Longest 1.27 (0.89–1.82) 1.45 (0.98–2.16) 1.25 (0.83–1.89) 0.81 (0.52–1.28) 1.12 (0.95–1.32)
All quartiles 1 1.10 (0.94–1.30) 0.91 (0.78–1.08) 0.94 (0.80–1.11)
* Po0.05, ** Po0.01.
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sother issues of access becoming more important in the furthest,
most rural travel quartile. The questions raised by the analysis that
we report need to be explored by detailed studies of access to
lung cancer services in primary care. Differences in uptake of
treatment have also been demonstrated in south east England
(Jack et al, 2003).
Because thoracic surgery was provided in a small number of
hospitals with more patients therefore having to travel further, a
clear distance decay effect was apparent with the patients living in
the furthest travel quartile being the least likely to undergo such
treatment. In a previous analysis of these data we showed that for
all lung cancer patients there was a distance decay effect for access
to thoracic surgery (Jones et al, 2008b); this included access both
to operative treatment and surgical diagnostic tests. The present
analysis shows independent effects of both travel time and social
deprivation in the sub-group of patients who have histologically
confirmed non-small cell lung cancer.
Where healthcare provision is mostly provided by private
insurance, as in the USA, it has been shown that lack of such
insurance is associated with more advanced stage at presentation
(Halpern et al, 2008). These data show that deprivation is very
important even when healthcare is provided free of charge.
Active treatment is associated with initial referral to a specialist
in lung cancer management (Jack et al, 2006). It is not possible in
this study to assess the effectiveness or otherwise of DGHs in
providing services, although there is clear evidence that patients
are more likely to receive chemotherapy, the definitive treatment
for small-cell lung cancer, if their closest hospital is either a
cancer centre or a DGH at which a non-surgical oncologist is
based. Patients whose closest diagnostic hospital was a DGH were
significantly less likely to undergo thoracic surgery compared with
those whose closest hospital was a cancer centre.
In planning services, it is necessary to make available
appropriate financial resources. There is strong evidence in these
data that by the attainment of a high rate of histological diagnosis
and higher rates of treatment in general and thoracic surgery in
particular, patients from the least deprived areas make the most
use of resources. In the NHS funding systems are weighted to
direct resources to meet the undeniable healthcare needs of
deprived people, but the increased consumption of resources by
people who are from affluent areas in the entirely appropriate
pursuit of diagnosis and treatment of lung cancer represents an
increased call on the relatively lower level of funding for their areas
of residence. This should be considered as one explanation for the
reported financial stress in the NHS organisations responsible for
such areas. To correct the geographical and especially social
inequities that we have shown, the NHS will probably require extra
capacity to meet the demand this will generate. It seems that
patients from more socioeconomically deprived areas could be
further disadvantaged if centralisation of services increased their
travel time to access them.
CONCLUSION
Attainment of histological diagnosis and receipt of active
treatment are strongly influenced by socioeconomic deprivation.
For the most deprived groups, disadvantage is amplified among
those with increased travel time to services. Further development
of NHS lung cancer services should therefore be directed at
overcoming both of these adverse influences on uptake.
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